4//SEC Filing
Revance Therapeutics, Inc. 4
Accession 0001209191-16-099587
CIK 0001479290operating
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 8:21 PM ET
Size
15.0 KB
Accession
0001209191-16-099587
Insider Transaction Report
Form 4
BYRNES ROBERT F
Director
Transactions
- Exercise/Conversion
Common Stock
2016-02-12$2.55/sh+5,333$13,599→ 10,999 total - Exercise/Conversion
Stock Option (Right to Buy)
2016-02-12−4,000→ 0 totalExercise: $6.60Exp: 2016-09-18→ Common Stock (4,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2016-02-12−1,666→ 0 totalExercise: $2.55Exp: 2020-07-20→ Common Stock (1,666 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2016-02-12−5,333→ 0 totalExercise: $2.55Exp: 2018-04-29→ Common Stock (5,333 underlying) - Exercise/Conversion
Common Stock
2016-02-12$6.60/sh+4,000$26,400→ 4,000 total - Exercise/Conversion
Common Stock
2016-02-12$2.55/sh+1,666$4,248→ 5,666 total
Holdings
- 2,666(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The Option was fully vested as of September 19, 2010.
- [F2]The Option was fully vested as of January 1, 2014.
- [F3]The Option was fully vested as of January 1, 2012.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001479290
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 8:21 PM ET
- Size
- 15.0 KB